Heart failure & cardiomyopathies
Distinct Comorbidity Clusters in Patients With Acute Heart Failure: Data From RELAX-AHF-2
Authors' conclusion
Comorbidities naturally clustered into 5 mutually exclusive groups in RELAX-AHF-2, showing variations in clinical outcomes.
Study context
- Population
- Patients with acute HF in RELAX-AHF-2 (26% HFpEF, LVEF ≥50%)validation n = 1,161
- Participants
- 6,545 patients
- Comparison
- Multimorbidity clusters vs young cluster
- Primary endpoint
- Composite outcome
Methodological detailslatent class analysis, external validation in RELAX-AHF
- Latent class analysis
- External validation in RELAX-AHF
Primary result
As reported in the abstract
Composite outcome (adjusted)
Each group vs youngHazard ratio (95% CI)
Diabetes and CKD
1.80(1.50–2.20)
Elderly/AF
1.42(1.20–1.70)
Metabolic
1.40(1.20–1.80)
Further findings
All-cause mortality, Young cluster (serelaxin-treated)
| HR (95% CI) | ||
|---|---|---|
| SerelaxinYoung group | 0.59 (0.40–0.90) | |
| 0.512Hazard ratio (log scale) |
Effect modification by treatment allocation (placebo or serelaxin)
- Treatment allocation modified associations
- P for interaction < 0.001
- Interaction P <0.001
Validation in RELAX-AHF
- Patients clustered in 5 multimorbidity groups; characteristics and outcome associations validated
Original publication
Distinct Comorbidity Clusters in Patients With Acute Heart Failure: Data From RELAX-AHF-2. JACC Heart Fail. Published 3 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →